UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS. James Hawkins 09/08/2025 James Hawkins 09/08/2025 Germany’s landmark compassionate use program for psilocybin: A new wave for psychedelic medicine in Europe Read More James Hawkins 09/08/2025 James Hawkins 09/08/2025 Psychedelic drug DMT and near death experiences have long been linked – my study is the first to explore the connection in depth Read More James Hawkins 09/08/2025 James Hawkins 09/08/2025 Health-related behavioral changes following the use of psychedelics in naturalistic settings Read More James Hawkins 20/07/2025 James Hawkins 20/07/2025 MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study Read More James Hawkins 16/07/2025 James Hawkins 16/07/2025 Psilocybin-assisted therapy for obsessive-compulsive disorder: A review Read More James Hawkins 16/07/2025 James Hawkins 16/07/2025 Naturalistic psychedelic use and changes in depressive symptoms Read More James Hawkins 16/07/2025 James Hawkins 16/07/2025 Psilocybin treatment extends cellular lifespan and improves survival of aged mice Read More James Hawkins 16/07/2025 James Hawkins 16/07/2025 Single-dose (10mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder Read More James Hawkins 05/07/2025 James Hawkins 05/07/2025 Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies Read More James Hawkins 02/07/2025 James Hawkins 02/07/2025 Medicinal cannabis use among people with obsessive compulsive disorder: Changes in quality of life after three months Read More James Hawkins 02/07/2025 James Hawkins 02/07/2025 Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial Read More James Hawkins 01/07/2025 James Hawkins 01/07/2025 Beckley’s 5-MeO-DMT shows rapid, durable antidepressant effects in phase 2b study Read More James Hawkins 23/06/2025 James Hawkins 23/06/2025 An investigation into the varieties of extended difficulties following psychedelic drug use: Duration, severity and helpful coping strategies Read More James Hawkins 23/06/2025 James Hawkins 23/06/2025 Long-term mental health and wellbeing outcomes associated with naturalistic ayahuasca consumption Read More James Hawkins 22/06/2025 James Hawkins 22/06/2025 Shamanism and psychedelics: 5 questions for Manvir Singh Read More James Hawkins 22/06/2025 James Hawkins 22/06/2025 MAPS brings MDMA-assisted therapy to the war in Ukraine Read More James Hawkins 18/06/2025 James Hawkins 18/06/2025 An international Delphi consensus for reporting of setting in psychedelic clinical trials Read More James Hawkins 18/06/2025 James Hawkins 18/06/2025 Long-term benefits of single-dose psilocybin in depressed patients with cancer Read More James Hawkins 08/06/2025 James Hawkins 08/06/2025 Psychedelic-assisted therapy: An overview for the internist Read More James Hawkins 08/06/2025 James Hawkins 08/06/2025 Addressing blinding in classic psychedelic studies with innovative active placebos Read More Older Posts
James Hawkins 09/08/2025 James Hawkins 09/08/2025 Germany’s landmark compassionate use program for psilocybin: A new wave for psychedelic medicine in Europe Read More
James Hawkins 09/08/2025 James Hawkins 09/08/2025 Psychedelic drug DMT and near death experiences have long been linked – my study is the first to explore the connection in depth Read More
James Hawkins 09/08/2025 James Hawkins 09/08/2025 Health-related behavioral changes following the use of psychedelics in naturalistic settings Read More
James Hawkins 20/07/2025 James Hawkins 20/07/2025 MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study Read More
James Hawkins 16/07/2025 James Hawkins 16/07/2025 Psilocybin-assisted therapy for obsessive-compulsive disorder: A review Read More
James Hawkins 16/07/2025 James Hawkins 16/07/2025 Naturalistic psychedelic use and changes in depressive symptoms Read More
James Hawkins 16/07/2025 James Hawkins 16/07/2025 Psilocybin treatment extends cellular lifespan and improves survival of aged mice Read More
James Hawkins 16/07/2025 James Hawkins 16/07/2025 Single-dose (10mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder Read More
James Hawkins 05/07/2025 James Hawkins 05/07/2025 Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies Read More
James Hawkins 02/07/2025 James Hawkins 02/07/2025 Medicinal cannabis use among people with obsessive compulsive disorder: Changes in quality of life after three months Read More
James Hawkins 02/07/2025 James Hawkins 02/07/2025 Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial Read More
James Hawkins 01/07/2025 James Hawkins 01/07/2025 Beckley’s 5-MeO-DMT shows rapid, durable antidepressant effects in phase 2b study Read More
James Hawkins 23/06/2025 James Hawkins 23/06/2025 An investigation into the varieties of extended difficulties following psychedelic drug use: Duration, severity and helpful coping strategies Read More
James Hawkins 23/06/2025 James Hawkins 23/06/2025 Long-term mental health and wellbeing outcomes associated with naturalistic ayahuasca consumption Read More
James Hawkins 22/06/2025 James Hawkins 22/06/2025 Shamanism and psychedelics: 5 questions for Manvir Singh Read More
James Hawkins 22/06/2025 James Hawkins 22/06/2025 MAPS brings MDMA-assisted therapy to the war in Ukraine Read More
James Hawkins 18/06/2025 James Hawkins 18/06/2025 An international Delphi consensus for reporting of setting in psychedelic clinical trials Read More
James Hawkins 18/06/2025 James Hawkins 18/06/2025 Long-term benefits of single-dose psilocybin in depressed patients with cancer Read More
James Hawkins 08/06/2025 James Hawkins 08/06/2025 Psychedelic-assisted therapy: An overview for the internist Read More
James Hawkins 08/06/2025 James Hawkins 08/06/2025 Addressing blinding in classic psychedelic studies with innovative active placebos Read More
